National Eye Institute; Notice of Meeting, 48288 [07-4100]
Download as PDF
<![CDATA[
48288
Federal Register / Vol. 72, No. 163 / Thursday, August 23, 2007 / Notices
ebenthall on PRODPC61 with NOTICES
measurements of a sequence common to
several targets.
The method’s software design allows
for large (>10,000) target sets and large
probe set sizes (2->1,000,000). While
current selection criteria involve a time
consuming iterative and manual
process, the present invention allows for
the identification of a quantitatively
optimized probe set which balances
probe performance criteria and
simultaneously optimizes the sensitivity
and specificity of the assay for a given
set of targets.
Applications: The invention has
applications in the design of various
important assays, such as those based
on microarrays, multiplexed PCR and
SPR, targeted protein fragment
detection, or any sequence-specific
binding and detection. It has application
where the number of probes to be used
in an assay is too large for manual
design and review.
Inventors: Eric Billings and Kevin E.
Brown (NHLBI).
Patent Status: U.S. Provisional
Application No. 60/871,447 filed 21 Dec
2006, entitled ‘‘Probe Set Global
Optimization’’ (HHS Reference E–332–
2005/0–US–01).
Development Status: The technology
is ready to be applied and validated in
many different areas for research and
diagnostic purposes.
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Cristina
Thalhammer-Reyero, Ph.D., M.B.A.;
301/435–4507; thalhamc@mail.nih.gov.
Collaborative Research Opportunity:
The National Heart, Lung and Blood
Institute, Computational Biophysics
Laboratory is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, utilize or
commercialize a method for optimizing
sequence-based assays. Please contact
Dr. Eric Billings, at (301) 496–6520 or
via e-mail at billings@helix.nih.gov for
more information.
Dated: August 16, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–16644 Filed 8–22–07; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
15:04 Aug 22, 2007
Jkt 211001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Advisory Eye Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Eye Council.
Date: September 27, 2007.
Closed: 8:30 a.m. to 10:30 a.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health, 5635
Fishers Lane, Terrace Level Conference
Center, Bethesda, MD 20982.
Open: 10:30 a.m. to Adjournment.
Agenda: Following opening remarks by the
Director, NEI there will be presentations by
the staff of the Institute and discussions
concerning Institute programs.
Place: National Institutes of Health, 5635
Fishers Lane, Terrace Level Conference
Center, Bethesda, MD 20892.
Contact Person: Lore Anne McNicol, PhD,
Director, Division of Extramural Research,
National Eye Institute, National Institutes of
Health, Bethesda, MD 20892, (301) 451–2020.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institutes’s/Center’s home page: https://
www.nei.nih.gov, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Dated: August 14, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–4100 Filed 8–21–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Supplementary Risk Assessments and
Site Suitability Analyses for the
National Emerging Infectious Disease
Laboratory, Boston University Medical
Center
Availability of Supplementary
Risk Assessments and Site Suitability
Analyses for the National Emerging
Infectious Disease Laboratory, Boston
University Medical Center; notice of
hearing.
ACTION:
SUMMARY: The National Institutes of
Health (NIH) has placed in the docket
for public review and comment the
Supplementary Risk Assessments and
Site Suitability Analyses for the
National Emerging Infectious Disease
Laboratory, Boston University Medical
Center, which address additional
concerns of the local community
regarding possible impacts of the
National Emerging Infectious Diseases
Laboratory, Boston University Medical
Center. The purpose of the
Supplementary Risk Assessments and
Site Suitability Analyses for the
National Emerging Infectious Disease
Laboratory was alternative site analysis
and risk assessment that investigated
potential infectious disease threats that
may be posed to the public should an
exotic infectious agent be released into
the community through an infected
laboratory worker, laboratory accident,
or other mishap.
DATES: Comments on the
Supplementary Risk Assessments and
Site Suitability Analyses for the
National Emerging Infectious Disease
Laboratory must be received by
Monday, November 12th. A public
hearing will be held on Thursday,
September 20, 2007, from 7–9 p.m. at
Faneuil Hall, Dock Square, Boston, MA
02109.
ADDRESSES: Comments should be sent to
Valerie Nottingham, Division of
Environmental Protection, National
Institutes of Health, 9000 Rockville
Pike, Building 13, Room 2S11,
Bethesda, MD 20892, MSC 5746. E-mail
comments should be sent to
nihnepa@mail.nih.gov. Comments sent
by e-mail must be received by 11:59
E:\FR\FM\23AUN1.SGM
23AUN1
]]>Agencies
[Federal Register Volume 72, Number 163 (Thursday, August 23, 2007)]
[Notices]
[Page 48288]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-4100]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of
the National Advisory Eye Council.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Eye Council.
Date: September 27, 2007.
Closed: 8:30 a.m. to 10:30 a.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: National Institutes of Health, 5635 Fishers Lane, Terrace
Level Conference Center, Bethesda, MD 20982.
Open: 10:30 a.m. to Adjournment.
Agenda: Following opening remarks by the Director, NEI there
will be presentations by the staff of the Institute and discussions
concerning Institute programs.
Place: National Institutes of Health, 5635 Fishers Lane, Terrace
Level Conference Center, Bethesda, MD 20892.
Contact Person: Lore Anne McNicol, PhD, Director, Division of
Extramural Research, National Eye Institute, National Institutes of
Health, Bethesda, MD 20892, (301) 451-2020.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institutes's/Center's home
page: https://www.nei.nih.gov, where an agenda and any additional
information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.867,
Vision Research, National Institutes of Health, HHS)
Dated: August 14, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-4100 Filed 8-21-07; 8:45 am]
BILLING CODE 4140-01-M
